The final rule placing diet drug lorcaserin in Schedule IV was published by the Drug Enforcement Administration May 8 (78 Fed. Reg. 26701). The drug is approved for marketing in the United States for use in weight management as an addition to a reduced-calorie diet and exercise. It will be marketed under the trade name BELVIQ. Effective June 27, 2013, handlers of products contain... Read More